Evidence map›Paper›PMID 28499442›Full record

ArticleJournal of experimental & clinical cancer research : CR2017

Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells.

Amani I Moraya, Jennifer L Ali, Pranati Samadder, Lisa Liang, Ludivine Coudière Morrison, Tamra E Werbowetski-Ogilvie, Makanjuola Ogunsina, Frank Schweizer, Gilbert Arthur, Mark W Nachtigal

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Amani I MorayaDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Jennifer L AliDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Pranati SamadderDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Lisa LiangDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Ludivine Coudière MorrisonDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Tamra E Werbowetski-OgilvieDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Makanjuola OgunsinaDept. of Chemistry, University of Manitoba, Winnipeg, Canada.
Frank SchweizerDept. of Chemistry, University of Manitoba, Winnipeg, Canada.
Gilbert ArthurDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada.
Mark W NachtigalDept. of Biochemistry & Medical Genetics, University of Manitoba, Room 333 BMSB, 745 Bannatyne Avenue, Winnipeg, R3E 0 W9, MB, Canada. mark.nachtigal@umanitoba.ca.
University of Manitoba · CACancerCare Manitoba · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundChemotherapy resistance is one of the major factors contributing to mortality from human epithelial ovarian cancer (EOC). Identifying drugs that can effectively kill chemotherapy-resistant EOC cells would be a major advance in reducing mortality. Glycosylated antitumour ether lipids (GAELs) are synthetic glycolipids that are cytotoxic to a wide range of cancer cells. They appear to induce cancer cell death in an apoptosis-independent manner.

methodsHerein, the effectiveness of two GAELs, GLN and MO-101, in killing chemotherapy-sensitive and -resistant EOC cells lines and primary cell samples was tested using monolayer, non-adherent aggregate, and non-adherent spheroid cultures.

resultsOur results show that EOC cells exhibit a differential sensitivity to the GAELs. Strikingly, both GAELs are capable of inducing EOC cell death in chemotherapy-sensitive and -resistant cells grown as monolayer or non-adherent cultures. Mechanistic studies provide evidence that apoptotic-cell death (caspase activation) contributes to, but is not completely responsible for, GAEL-induced cell killing in the A2780-cp EOC cell line, but not primary EOC cell samples.

conclusionsStudies using primary EOC cell samples supports previously published work showing a GAEL-induced caspase-independent mechanism of death. GAELs hold promise for development as novel compounds to combat EOC mortality due to chemotherapy resistance.

Indexed as

Antineoplastic AgentsApoptosisCarcinoma, Ovarian EpithelialCell DeathCell Line, TumorCell ProliferationCells, CulturedCell SurvivalCisplatinDose-Response Relationship, DrugDrug Resistance, NeoplasmGlycolipidsHumansNeoplasms, Glandular and EpithelialOvarian NeoplasmsPepstatinsAntineoplastic AgentsCisplatinGlycolipidspepstatinPepstatinsDrug-resistanceGlycosylated anti-tumour ether lipidOvarian cancerSpheroid

Identifiers

PMID28499442
PMCPMC5429581
OpenAlexW2614094721

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.